首页 | 本学科首页   官方微博 | 高级检索  
     


Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situhybridization and immunohistochemistry
Authors:Marta?Salido  author-information"  >  author-information__contact u-icon-before"  >  mailto:MSALIDO@IMAS.IMIM.ES"   title="  MSALIDO@IMAS.IMIM.ES"   itemprop="  email"   data-track="  click"   data-track-action="  Email author"   data-track-label="  "  >Email author,Ignasi?Tusquets,Josep?M?Corominas,Marta?Suarez,Blanca?Espinet,Cristina?Corzo,Xavier?Fabregat,Sergi?Serrano,Francesc?Solé
Affiliation:1.Laboratori de Citogenètica i Biologia Molecular, Servei de Patologia,Hospital del Mar, IMAS,Barcelona,Spain;2.Escola de Citologia Hematològica S Woessner-IMAS,Hospital del Mar, IMAS-IMIM,Barcelona,Spain;3.Unitat de Recerca translacional en tumors sòlids-IMAS,Barcelona,Spain;4.Servei d'Oncologia Mèdica,Hospital del Mar, IMAS,Barcelona,Spain;5.Universitat Autònoma de Barcelona,Barcelona,Spain;6.Servei de Patologia,Hospital del Mar, IMAS,Barcelona,Spain
Abstract:

Introduction  

One of the most common genetic aberrations associated with breast cancer is the amplification and overexpression of the ERBB2 proto-oncogene located at chromosome 17, bands q12-21. The amplification/overexpression occurs in 25 to 30% of all breast cancers. In breast cancer, aneusomy of chromosome 17, either monosomy or polysomy, is frequently observed by conventional cytogenetics and fluorescence in situ hybridization (FISH). The aim of this study was to discover whether or not numerical aberrations on chromosome 17 have a correlation to the amplification or overexpression of the ERBB2 gene and to analyze their clinical implications in subgroups showing 2+ or 3+ positive scores by immunohistochemistry (IHC).
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号